STOCK TITAN

Gossamer Bio, Inc. - GOSS STOCK NEWS

Welcome to our dedicated news page for Gossamer Bio (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gossamer Bio 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gossamer Bio 's position in the market.

Rhea-AI Summary
Gossamer Bio, Inc. (GOSS) to Initiate Phase 3 PROSERA Study in PAH Patients, Expects Additional Data from TORREY Open-Label Extension. $374 Million in Cash, Cash Equivalents & Marketable Securities as of June 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
-
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) announced a conference call with PAH experts to discuss the upcoming PROSERA Phase 3 study and an interim update of the Phase 2 TORREY open-label extension for the treatment of pulmonary arterial hypertension (PAH). The call will be held on Tuesday, July 25th at 10 a.m. EDT. Investors and analysts can access the live audio webcast through the company's website or via phone. The discussion will feature world-renowned PAH key opinion leaders, Dr. Ray Benza, Dr. Ardi Ghofrani, and Dr. Jim White.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.72%
Tags
-
Rhea-AI Summary
Gossamer Bio, Inc. has entered into a securities purchase agreement to sell securities in a private placement for gross proceeds of approximately $212 million. The financing includes participation from new and existing institutional investors. The company plans to use the net proceeds to fund the ongoing development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.87%
Tags
none
Rhea-AI Summary
Gossamer Bio, Inc. (Nasdaq: GOSS) announced that data from its Phase 2 TORREY Study of seralutinib in patients with pulmonary arterial hypertension (PAH) will be presented at the American Thoracic Society 2023 International Conference. The results were positive, leading Gossamer to plan a Phase 3 clinical trial in the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.48%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-74.6%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.9%
Tags
none
Gossamer Bio, Inc.

Nasdaq:GOSS

GOSS Rankings

GOSS Stock Data

160.05M
190.99M
2.25%
93.16%
4.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About GOSS

gossamer bio is a san diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. founded by the former receptos executive team, gossamer bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.